Dr Kasper discusses the FDA approval of nirogacestat for patients with progressing desmoid tumors; key efficacy, safety, and quality-of-life outcomes from the pivotal DeFi trial; and findings from an analysis investigating tumor volume and T2 hyperintensity changes with nirogacestat in patients enrolled in DeFi.
Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses the effect of nirogacestat on tumor volume and T2 hyperintensity in patients with desmoid tumors.
Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject to approval by Ayala’s shareholders.
Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid Tumors - read this article along with other careers information, tips and advice on BioSpace